Bridge Capture™ enables sensitive, scalable liquid biopsy in colorectal cancer pilot

Clinical study in Scientific Reports shows Bridge Capture™ detects key mutations from blood samples in metastatic colorectal cancer patients

TURKU, Finland, July 14, 2025 /CNW/ -- Genomill Health, a biotechnology company pioneering simplified targeted library preparation for next-generation sequencing announces the results of a clinical pilot study published in Scientific Reports, demonstrating the high sensitivity of its Bridge Capture™ technology for mutation profiling in cell free DNA of metastatic colorectal cancer patients. Study shows that Bridge Capture™ matches the sensitivity of droplet digital PCR (ddPCR) - a gold standard in the field - while providing unlimited panel scalability and simple and cost-efficient workflow that enables decentralized NGS testing.